Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Bumps Up Sales Target

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2019 | 07:39am EDT

By Kimberly Chin

Johnson & Johnson raised its sales guidance in the latest quarter as the company continues to expand its pipeline and wins regulatory approvals.

The New Jersey-based company now expects reported sales for the year to be between $80.8 billion to $81.6 billion, up from $80.4 billion to $81.2 billion previously forecast.

J&J's profit climbed 42% for the second quarter to $5.61 billion, or $2.08 a share, from the comparable quarter a year ago. Analysts polled by FactSet expected earnings of $2.17 a share. Excluding special items, J&J made $2.58 a share, beating analysts' estimates of $1.94 a share.

Sales in its pharmaceuticals division in the U.S slipped by about 2% to $5.78 billion. Sales in its medical-devices business also fell 5.6% to $3.08 billion while sales in its U.S. consumer segment rose 4.1% to $5.78 billion.

Overall world-wide sales declined slightly from a year ago to $20.56 billion. Analysts expected $20.29 billion in sales.

In the past quarter, the company garnered some regulatory approvals for Imbruvica, an oral treatment for a type of lymph-node cancer, and Darzalex, which treats multiple myeloma.

Shares rose 0.8% in premarket trading.

Write to Kimberly Chin at kimberly.chin@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/21JOHNSON & JOHNSON : Trump signs student debt forgiveness for disabled veterans
AQ
08/21JOHNSON & JOHNSON : Oklahoma judge expected to rule Monday in opioid case
AQ
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
AQ
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
PU
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 5 892 M
Yield 2019 2,86%
P/E ratio 2019 19,6x
P/E ratio 2020 17,3x
EV / Sales2019 4,33x
EV / Sales2020 4,07x
Capitalization 347 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 131,53  $
Spread / Highest target 28,5%
Spread / Average Target 12,9%
Spread / Lowest Target -5,72%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.20%347 129
ROCHE HOLDING LTD.12.16%238 668
MERCK AND COMPANY13.74%222 522
NOVARTIS17.97%206 833
PFIZER-20.71%192 868
NOVO NORDISK AS15.68%123 385